Main Points:
– Viking Therapeutics (VKTX) saw a 146% increase in shares over two days after announcing positive Phase II trial results for VK2735 in patients with obesity.
– Zealand Pharma (ZEAL) impressed investors with the success of survodutide (BI 456906) in meeting its primary endpoint in a Phase II trial.
Author’s Take:
Viking Therapeutics and Zealand Pharma made significant strides in the biotech world with positive trial results that resonated well with investors, leading to substantial stock increases. The promising outcomes from these trials showcase the potential for innovative therapies in addressing conditions like obesity, hinting at a competitive landscape that could challenge established players in the industry.
Click here for the original article.